Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Chimerix, Inc. CMRX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$8.55
+0.1%

Chimerix, Inc. (CMRX) is a Biotechnology company in the Healthcare sector, currently trading at $8.54. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is CMRX = $9 (+0.1% upside).

Financials: revenue is $212,000, +491.8%/yr average growth. Net income is $88M (loss), growing at +4%/yr. Net profit margin is -41692% (negative). Gross margin is 100% (+23.6 pp trend).

Balance sheet: total debt is $458,000 against $122M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 5.7 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $146M.

Analyst outlook: 14 / 25 analysts rate CMRX as buy (56%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 73/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 56/100 (Partial), Future 46/100 (Partial), Income 10/100 (Fail).

$8.55
▲ 0.12% Upside
Average Price Target
The 12-month price target for Chimerix, Inc. is $8.55.

CMRX SharesGrow Score Overview

51/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 56/100
Gross margin is + market cap
FUTURE 46/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CMRX

~
VALUE Partial
50/100
CMRX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $9, implying +5.4% from the current price $9. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
73/100
CMRX: +491.8%/yr revenue is, +4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
CMRX: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet CMRX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 5.7 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
56/100
CMRX: Gross margin is 100% (+23.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 56/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
46/100
Analyst outlook: 14 / 25 analysts rate CMRX as buy (56%). Analyst consensus target is $9 (+5.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
CMRX: Net profit margin is -41692%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.75-8.55
Volume2.55M
Avg Volume (30D)4.05M
Market Cap$801.08M
Beta (1Y)-0.18
Share Statistics
EPS (TTM)-0.99
Shares Outstanding$89.7M
IPO Date2013-04-11
Employees79
CEOMichael T. Andriole
Financial Highlights & Ratios
Revenue (TTM)$212K
Gross Profit$212K
EBITDA$-96.47M
Net Income$-88.39M
Operating Income$-96.57M
Total Cash$31.05M
Total Debt$458K
Net Debt$-30.59M
Total Assets$146.01M
Price / Earnings (P/E)-8.6
Price / Sales (P/S)3778.7
Analyst Forecast
1Y Price Target$8.55
Target High$8.55
Target Low$8.55
Upside+0.1%
Rating ConsensusBuy
Analysts Covering25
Buy 56% Hold 36% Sell 8%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS16934W1062

Price Chart

Track all markets on TradingView
CMRX
Chimerix, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.75 52WK RANGE 8.55

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 MREO
MREO
Mereo BioPharma Group plc
$0.33
+2.81%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message